Unveiling the future of cell and gene therapies in the UK
In recent years, cell and gene therapies have been advancing at lightning speed, offering new hope to…
Twitter outputted an error:
Invalid or expired token..
Invalid or expired token..
LifeArc welcomes news of the UK rejoining Horizon Europe, the EU science research scheme
Today the UK and EU agreed a deal for the UK to associate the world’s largest collaborative…
LifeArc and the Francis Crick Institute partner with five African research institutions to support scientists
LifeArc is partnering with the Francis Crick Institute to invest £7.5m to support African scientists to address unmet…
LifeArc joins Infection Innovation Consortium to help tackle infectious diseases
LifeArc are partnering with Liverpool School of Tropical Medicine (LSTM) to launch a new development fund to…
New Alzheimer’s treatment ‘lecanemab’ approved for use in the US
LifeArc played an instrumental role in the drug’s development through our antibody humanisation work.
LifeArc and DEBRA Austria launch £2.5m funding call for repurposing therapies for Epidermolysis Bullosa
Joint initiative part of LifeArc’s £100 million Translational Challenge to help address rare disease translational science.
Catriona Crombie talks to Rare Revolution about LifeArc’s investment of more than £100 million into rare disease research by 2030
Catriona discusses why LifeArc is well placed to help overcome some of the obstacles in rare disease research
Groundbreaking new £100m LifeArc programme aims to improve the lives of people living with a rare disease
Brings together the world-leading expertise of Health Data Research UK, University of Edinburgh, LifeArc, Eisai and Gates Ventures
New UK-based research project brings together world-leading institutions to transform care for people living with dementia
Brings together the world-leading expertise of Health Data Research UK, University of Edinburgh, LifeArc, Eisai and Gates Ventures